Test ID: EGFR
EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Identifying non-small cell lung cancers that may respond to epidermal growth factor receptor-tyrosine kinase inhibitor therapies
Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SLRVW | Slide Review | No | Yes |
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
When this test is ordered, slide review will always be performed at an additional charge.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
Polymerase Chain Reaction (PCR) Analysis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
EGFR Gene, Mutation Analysis, Tumor
Aliases Lists additional common names for a test, as an aid in searching
EGFR
Epidermal growth factor receptor
Gefitinib
Erlotinib
EGFR-TKI
EGFR-tyrosine kinase inhibitor
Non-small cell lung cancer
NSCLC
Epidermal growth factor receptor
Gefitinib
Erlotinib
EGFR-TKI
EGFR-tyrosine kinase inhibitor
Non-small cell lung cancer
NSCLC
External
link
PDF
document
Excel
document
Word
document